Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models

Neurobiology of Aging

Volumn 27, Issue 8, 2006, Pages 1060-1077

  Reddy, P Hemachandra ^a   McWeeney, Shannon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Animal models; Gene expression; Mitochondria; Transcriptosomes

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; MESSENGER RNA; OLIGOMER; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; ANAMNESIS; AUTOPSY; BIOCHEMISTRY; BIOINFORMATICS; BRAIN TISSUE; CADAVER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; FLY; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE MAPPING; GENETIC ENGINEERING; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GONADAL AGENESIS; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; MEDICAL INFORMATICS; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NEUROSCIENCE; NONHUMAN; ONSET AGE; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TISSUE MICROARRAY; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; VALIDATION PROCESS; WORM;

ALZHEIMER DISEASE; ANIMALS; AUTOPSY; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS;

EID: 33744925947     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.04.014     Document Type: Review

References (162)

1. Acquati F., Accarin M., Nucci C., Fumagalli P., Jovine L., Ottolenghi O., et al. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett (2000) 59-64
2. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Geddes J.W., and Markesbery W.R. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103 (2001) 373-383
3. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86 (2003) 582-590
4. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., et al. Progressive age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891 (2001) 42-43
5. Avila J., Lucas J.J., Perez M., and Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 84 (2004) 361-384
6. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1366 (1998) 211-213
7. Bennett B.D., Babu-Khan S., Loeloff R., Louis J.C., Curran E., Citron M., et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275 (2000) 20647-20651
8. Berg L., Mckeel Jr. D.W., Miller J.P., et al. Neuropathological indexes of Alzheimer's diseases in demented and non-demented personsaged 80 years and older. Arch Neurol 50 (1993) 349-358
9. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and Laferla F.M. Intraneuronal abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
10. Blalock E.M., Geddes J.W., Chen K.C., Porter N.M., Markesbery W.R., and Landfield P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101 (2004) 2173-2178
11. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (1997) 939-945
12. Braak H., and Braak E. Neuropathological staging Alzheimer-related changes. Acta Neuropathol 82 (1991) 239-259
13. Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29 (2001) 365-371
14. Cheetham J.E., Coleman P.D., and Chow N. Isolation of single immunohistochemically identified whole neuronal cell bodies from post-mortem human brain for simultaneous analysis of multiple gene expression. J Neurosci Methods 77 (1997) 43-48
15. Chen F., Wollmer M.A., Hoerndli F., Munch G., Kuhla B., Rogaev E.I., et al. Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci USA 101 (2004) 7687-7692
16. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276 (2001) 21562-21570
17. Chow N., Cox C., Callahan L.M., Weimer J.M., Guo L., and Coleman P.D. Expression profiles of multiple genes in single neurons of Alzheimer's disease. Proc Natl Acad Sci USA 95 (1998) 9620-9625
18. Cirrito J.R., and Holtzman D.M. Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details. J Clin Invest 112 (2003) 321-323
19. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8 (2005) 79-84
20. Colangelo V., Schurr J., Ball M.J., Pelaez R.P., Bazan N.G., and Lukiw W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 70 (2002) 462-473
21. Davies C.A., Mann D.M.A., Sumpter P.Q., and Yates P.O. A quantitative morphometric analysis of the synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neuro Sci 78 (1987) 151-164
22. Dekosky S.T., Scheff S.W., and Styren S.D. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 5 (1999) 417-421
23. Dewachter I., Moechars D., van Dorpe J., Tesseur I., Van den Haute C., Spittaels K., et al. Modelling Alzheimer's disease in multiple transgenic mice. Biochem Soc Symp 67 (2001) 203-210
24. Dickey C.A., Loring J.F., Montgomery J., Gordon M.N., Eastman P.S., and Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23 (2003) 5219-5226
25. Dodd P.R., Hambley J.W., Cowburn R.F., and Hardy J.A. A comparison of methodologies for the study of functional transmitter neurochemistry in human brain. J Neurochem 50 (1988) 1333-1345
26. Doyu M., Sawada K.I., Mitsuma N., Niwa J.I., Yahshimoto M., Fujii Y., et al. Gene expression profile in Alzheimer's brain screened by molecular indexing. Mol Brain Res 87 (2000) 1-11
27. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., et al. Increased amyloid 42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
28. Echeverria V., and Cuello A.C. Intracellular A-beta amyloid, a sign for worse things to come?. Mol Neurobiol 26 (2002) 299-316
29. Edbauer D., Kaether C., Steiner H., and Haass C. Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1. J Biol Chem 279 (2004) 37311-37315
30. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95 (1998) 14863-14868
31. Flood D.G., Reaume A.G., Dorfman K.S., Lin Y.G., Lang D.M., Trusko S.P., et al. FAD mutant PS-1 gene-targeted mice: increased A42 and A deposition without APP overproduction. Neurobiol Aging 23 (2002) 335-348
32. Forloni G., Terreni L., Bertani I., Fogliarino S., Invernizzi R., Assini A., et al. Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging 23 (2002) 957-976
33. Forman M.S., Lee V.M., and Trojanowski J.Q. Unfolding pathways in neurodegenerative disease. Trends Neurosci 26 (2003) 407-410
34. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
35. Ge Y.W., Ghosh C., Song W., Maloney B., and Lahiri D.K. Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region. J Neurochem 90 (2004) 1432-1444
36. Gemma C., Mesches M.H., Sepesi B., Choo K., Holmes D.B., and Bickford P.C. Diets enriched in foods with high antioxidant activity reverse age-induced decreases in cerebellar beta-adrenergic function and increases in proinflammatory cytokines. J Neurosci 22 (2002) 6114-6120
37. Gerry N.P., Witowski N.E., Day J., Hammer R.P., Barany G., and Barany F. Universal DNA microarray method for multiplex detection of low abundance point mutations. J Mol Biol 292 (1999) 251-262
38. Geschwind D.H. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg. Neuron 40 (2003) 457-460
39. Gibson G.E. Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease. Free Radic Biol Med 32 (2001) 1061-1070
40. Ginsberg S.D., Hemby S.E., Lee V.M., Eberwine J.H., and Trojanowski J.Q. Expression profile of transcripts in Alzheimer's disease tangle bearing CA1 neurons. Ann Neurol 48 (2000) 77-87
41. Ginsberg S.D., and Che S. Combined histochemical staining, RNA amplification, regional, and single cell cDNA analysis within the hippocampus. Lab Invest 84 (2004) 952-962
42. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
43. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., et al. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLS) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100 (2003) 10417-10422
44. Gotz J., Spillantini M.G., Schafer T., Jakes R., Burki K., and Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14 (1995) 1304-1313
45. Gotz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 9 7 (2004) 664-683
46. Greeve I., Kretzschmar D., Tschape J.A., Beyn A., Brellinger C., Schweizer M., et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. Neurobiol Dis 24 (2004) 3899-3906
47. Grunblatt E., Hoyer S., and Riederer P. Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. J Neural Transm 111 (2004) 367-386
48. Gutala R.V., and Reddy P.H. The use of real-time PCR analysis in a gene expression study of Alzheimer's disease postmortem brain. J Neurosci Methods 132 (2004) 101-107
49. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
50. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
51. Hardy J.A., Wester P., Winblad B., Gezelius C., Bring G., and Eriksson A. The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J Neural Transm 61 (1985) 253-264
52. Harrison P.J., Heath P.R., Eastwood S.L., Burnet P.W., McDonald B., and Pearson R.C. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett 200 (1995) 151-154
53. Harrison P.J., Procter A.W., Exworthy T., Roberts G.W., Najlerahim A., Barton A.J.L., et al. Heat shock protein (hsx70) mRNA expression in human brain: effects of neurodegenerative disease and agonal state. Neuropathol Appl Neurobiol 19 (1993) 1021
54. Hata R., Masumura M., Akatsu H., Li F., Fujita H., Nagai Y., et al. Up-regulation of calcineurin Aβ mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. Biochem Biophys Res Commun 284 (2001) 310-316
55. Hemby S.E., Trojanowski J.Q., and Ginsberg S.D. Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. J Comp Neurol 456 (2003) 176-183
56. Hiltunen M., Mannermaa A., Thompson D., Easton D., Pirskanen M., Helisalmi S., et al. Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. Neurology 57 (2001) 1663-1668
57. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21 (2001) 3017-3023
58. Ho L., Guo Y., Spielman L., Petrescu O., Haroutunian V., Purohit D., et al. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett 298 (2001) 191-194
59. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotypein transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4 (1998) 97-100
60. Hollingshead D., Lewis D.A., and Mirnics K. Platform influence in DNA microarray data in postmortem brain research. Neurbiol Dis 18 (2005) 647-655
61. Holmes C. Genotype and phenotypes in Alzheimer's disease. Br J Psychiatry 180 (2002) 131-134
62. Hoozemans J.J., Rozemuller A.J., Veerhuis R., and Eikelenboom P. Immunological aspects of Alzheimer's disease: therapeutic implications. BioDrugs 15 (2001) 325-337
63. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits. A beta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
64. Hyman B.T., Van Hoesen G.W., Kromer L.J., and Damaseo A.R. Perforant pathway changes in the memory impairment of Alzheimer's disease. Ann Neurol 20 (1986) 472-481
65. Iijima K., Liu H.P., Chiang A.S., Hearn S.A., Konsolaki M., and Zhong Y. Dissecting the pathological effects of human Aβ42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci USA 101 (2004) 6623-6628
66. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13 (2004) 159-170
67. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., and Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17 (2001) 157-165
68. Kammoun S., Gold G., Bouras C., Giannakopoulos P., McGee W., Herrmann F., et al. Immediate causes of death of demented and non-demented elderly. Acta Neurol Scand 176 (2000) 9699
69. Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 24 (2004) 3801-3809
70. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
71. Keene J., Hope T., Fairburn C.G., and Jacoby R. Death and Dementia. Int J Geriat Psychiat 16 (2001) 969-974
72. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 24 (2001) 219-224
73. Kulnane L.S., and Lamb B.T. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 8 (2001) 982-992
74. Kurt M.A., Davies D.C., Kidd M., Duff K., and Howlett D.R. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol Dis 14 (2003) 89-97
75. Lahiri D.K., Ge Y.W., Maloney B., Vrièze F.W.D., and Hardy J. Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease. Neurobiol Aging 26 (2005) 1329-1341
76. Lahiri DK, Ge YW, Maloney B. Characterization of the APP proximal promoter and 5′-untranslated regions: identification of cell-type specific domains and implications in APP gene expression and Alzheimer's disease. FASEB J, 9 February 2005 [Epub ahead of print].
77. Lamb B.T., Call L.M., Slunt H.H., Bardel K.A., Lawler A.M., Eckman C.B., et al. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet 6 (1997) 1535-1541
78. Lamb B.T., Bardel K.A., Kulnane L.S., Anderson J.J., Holtz G., Wagner S.L., et al. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci 2 (1999) 695-697
79. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
80. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Mirnics Z.K., Lee V.M.Y., et al. Environmental enrichment reduces levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-713
81. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 24 (2001) 1121-1159
82. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25 (2000) 402-405
83. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269(5226 (August)):973-7.
84. Link C.D., Taft A., Kapulkin V., Duke K., Kim S., Fei Q., et al. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol Aging 24 (2003) 397-413
85. Loring J.F., Wen X., Lee J.M., Seilhamer J., and Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol 20 (2001) 683-695
86. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004) 448-452
87. Manczak M., Park B.S., Jung Y., and Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromol Med 5 (2004) 147-162
88. Manczak M., Yung Y., Park B.S., Partovi D., and Reddy P.H. Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage and cytochrome c in aging. J Neurochem 92 (2005) 494-504
89. Margolin J. Of mice men and the genome. Genome Res 10 (2000) 1431-1432
90. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol 9 (1999) 133-146
91. Masliah E., Mallory M., and Hansen L. Synaptic neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174 (1994) 67-72
92. Mattson M.P., LaFerla F.M., Chan S.L., Leissring M.A., Shepel P.N., and Geiger J.D. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 23 (2000) 222-229
93. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
94. McGeer P.L. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 17 (2000) 1-11
95. Mehta N.D., Refolo L.M., Eckman C., Sanders S., Yager D., Perez-Tur J., et al. Increased Abeta 42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43 (1998) 256-268
96. Mirnics K., and Pevsner J. Progress in the use of microarray technology in neurobiology of disease. Nat Neurosci 7 (2004) 1-7
97. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., and Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28 (2000) 53-67
98. Mirnics K., Korade Z., Arion D., Lazarov O., Unger T., Macioce M., et al. Presenilin-1 dependent transcriptome changes. J Neurosci 25 (2005) 1571-1578
99. Mirnics Z.K., Mirnics K., Terrano D., Lewis D.A., Sisodia S.S., and Schor N.F. DNA microarray profiling of developing PS1-deficient mouse brain reveals complex and coregulated expression changes. Mol Psychiatry 8 (2003) 863-878
100. Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420:520-62.
101. Mrak R.E., and Griffin W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 22 (2001) 903-908
102. Mufson E.J., Counts S.E., and Ginsberg S.D. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochem Res 27 (2002) 1035-1048
103. Murphy M.P., Das P., Nyborg A.C., Rochette M.J., Dodson M.W., Loosbrock N.M., et al. Overexpression of nicastrin increases Abeta production. FASEB J 17 9 (2003) 1138-1140
104. Neve R.L., Harris P., Kosik K.S., Kurnit D.M., and Donlon T.A. Identification of cDNA clones for the human microtubule associated protein tau and chromosomal location of the genes for tau and microtubule associated protein 2. Brain Res 387 (1986) 271-280
105. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38 (2003) 555-565
106. Nordberg A. Toward an early diagnosis and treatment of Alzheimer's disease. Int Psychogeriatr 15 (2003) 223-237
107. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421
108. Pepeu G. Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 193-209
109. Price D.L., and Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Ann Rev Neurosci 21 (1998) 479-505
110. Puig B., Gomez-Isla T., Ribe E., Cuadrado M., Torrejon-Escribano B., Dalfo E., et al. Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30 (2004) 491-502
111. Quackenbush J. Microarray data normalization and transformation. Nat Genet 32 (2002) 496-501
112. Raber J. Androgens, apoE, and Alzheimer's disease. Sci Aging Knowledge Environ 11 (2004) re2
113. Raber J., Huang Y., and Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25 (2004) 641-650
114. Rat Genome Consortium. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004;428:493-521.
115. Reddy P.H., McWeeney S., Park B.S., Manczak M., Gutala R.V., Partovi D., et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: upregulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13 (2004) 1225-1240
116. Reddy P.H., Mani G., Park B.S., Jaques J., Murdoch G., Whetsell Jr. W., et al. Differential loss of synaptic proteins in Alzheimer's disease patients: implications to synaptic damage. J Alzheimer's Dis 7 (2005) 103-117
117. Reddy PH, Beal FM. Are mitochondrial critical in the pathogenesis of Alzheimer's disease. Brain Res Rev, in press.
118. Rogers J., Webster S., Lue L.F., Brachova L., Civin W.H., Emmerling M., et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17 (1996) 681-686
119. Samuel W., Masliah E., and Terry R. Hippocampal connectivity and Alzheimer's dementia: effects of pathology in a two component model 44 (1994) 2081-2088
120. Saunders A.J., Kim T.W., and Tanzi R.E. BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. Science 286 (1999) 1255a
121. Scearce L.M., Brestelli J.E., McWeeney S.K., Lee C.S., Mazzarelli J., Pinney D.F., et al. Functional genomics of the endocrine pancreas: the pancreas clone set and PancChip, new resources for diabetes research. Diabetes 15 (2002) 1997-2004
122. Schellenberg G.D., Bird T.D., Wijsman E.M., Orr H.T., Anderson L., Nemens E., et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258 5082 (October) (1992) 668-671
123. Schena M., and Davis R.W. Genes, genomes and chips. In: Schena M. (Ed). DNA Microarrays-A Practical Approach (1999), Oxford University Press, Oxford, New York 1-15
124. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
125. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 (1992) 126-129
126. Selkoe D.J. The genetics and molecular biology of Alzheimer's disease: roles of amyloid and presenilins. Neurol Clin 18 (2000) 903-922
127. Selkoe D.J. Alzheimer's disease: genes, proteins and therapy. Physiol Rev 81 (2001) 741-766
128. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
129. Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., et al. Purification and cloning of amyloid precursor protein-secretase from human brain. Nature 402 (1999) 537-540
130. Sisodia S.S., Annaert W., Kim S.H., and De Strooper B. Gamma-secretase: never more enigmatic. Trends Neurosci 24 (2001) S2-S6
131. Sisodia S.S., and St George-Hyslop P.H. Gamma-secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?. Nat Rev Neurosci 3 (2002) 281-290
132. Small D.H., Mok S.S., and Bornstein J.C. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2 (2001) 595-598
133. Spittaels K., Van den Haute C., Van Dorpe J., Bruynseels K., Vandezande K., Laenen I., et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155 (1999) 2153-2165
134. Stackman R.W., Eckenstein F., Frei B., Kulhanek D., Nowlin J., and Quinn J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 184 (2003) 510-520
135. Stein T.D., and Johnson J.A. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22 (2002) 7380-7388
136. Sturn A., Quackenbush J., and Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 18 (2002) 207-208
137. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94 (1997) 13287-13292
138. Suh Y.H., and Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 5 (2002) 469-525
139. Swerdlow R.H., and Khan S.M. "Mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypothesis 63 (2004) 8-20
140. Tanzi R.E., and Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 32 (2001) 181-184
141. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hil R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 (1991) 572-580
142. Terry R.D. Neuropathologial changes in Alzheimer's disease. Prog Brain Res 10 (1994) 383-390
143. Tomita H., Vawter M.P., Walsh D.M., Evans S.J., Choudary P.V., Li J., et al. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 55 4 (2004) 346-352
144. The C. Elegans sequencing consortium. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 282 (1998) 2012-2018
145. Therianos S., Zhu M., Pyun E., and Coleman P.D. Single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction for large numbers of gene products differentiates nondemented from neuropathological Alzheimer's disease. Am J Pathol 164 (2004) 795-806
146. Thibault O., Porter N.M., Chen K.C., Blalock E.M., Kaminker P.G., Clodfelter G.V., et al. Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions. Cell Calcium 24 (1998) 417-433
147. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
148. Vassar R. β-Secretase (BASE) as a drug target for Alzheimer's disease. Adv Drug Del Rev 54 (2002) 1589-1602
149. Venter C.J., et al. The sequence of human genome. Science 291 (2001) 1304-1351
150. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-559
151. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
152. Wang G., Zhang Y., Chen B., and Cheng J. Preliminary studies on Alzheimer's disease using cDNA microarrays. Mech Aging Dev 124 (2003) 115-124
153. Watterson D.M., Velentza A.V., Zasadzki M., Craft J.M., Haiech J., and Van Eldik L.J. Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression. J Mol Neurosci 20 (2003) 411-423
154. Weisgraber K.H., Rall Jr. S.C., and Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 256 (1982) 9077-9083
155. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22 (2002) 1858-1867
156. Wisniewski T., and Sigurdsson E.M. Immunization treatment approaches in Alzheimer's and prion diseases. Curr Neurol Neurosci Rep 2 (2002) 400-404
157. Xia W., Zhang J., Ostaszewski B.L., Kimberly W.T., Seubert P., Koo E.H., et al. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry 37 (1998) 16465-16471
158. Yang G.P., Ross D.T., Kuang W.W., Brown P.O., Weigel R.J., and Combining. SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucl Acid Res 27 (1999) 1517-1523
159. Yao P.J., Zhu M., Pyun E.I., Brooks A.I., Therianos S., Meyers V.E., et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 12 (2003) 97-109
160. Yu G., Nishimura M., Arawaka S., Levitan D., Zhang L., Tandon A., et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 407 (2000) 48-54
161. Zhang Q., Powers E.T., Nieva J., Huff M.E., Dendle M.A., Bieschke J., et al. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci USA 101 (2004) 4752-4757
162. Zhang X. Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease. Curr Drug Target CNS Neurol Disord 3 (2004) 137-152